LJP 1082

DB05446ExperimentalSmall molecule

LJP 1082 is a Toleragen that is designed to shut down the B cells that produce antibodies to ß2 GP1. LJP 1082 is undergoing trial for for the treatment of... LJP 1082 is undergoing trial for for the treatment of stroke, deep-vein thrombosis and other conditions associated with antibody-mediated thrombosis.

Mechanism: The target of the LJP 1082's clot-promoting antibodies is a small region on a key blood protein called beta 2-glycoprotein I.
Curator reviewed
Primary indication: Investigated for use/treatment in autoimmune diseases, strokes, and thrombosis.Curator reviewed
Formula / weight: C₁₁H₁₉N₃O₇S · 337.349 g/mol (avg)
Code names: LJP 1082

Resolves to

Compound

PubChem1082

Structure

InChIKeyPIUSLWSYOYFRFR-UHFFFAOYSA-NSMILESNC(CCC(=O)NC(CSCO)C(=O)NCC(O)=O)C(O)=O

Targets

P02749APOH

What you can answer from here — as of April 02, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with LJP 1082, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account